Literature DB >> 16369846

[Revision of tumour endoprostheses around the knee joint. Review and own results].

R Windhager1, A Leithner, M Hochegger.   

Abstract

Revision of tumour endoprostheses around the knee joint is mainly caused by aseptic loosening and deep infection. Mechanical complications have been significantly reduced by improvements in prosthetic design. The rate of aseptic loosening after distal femur or proximal tibia replacement ranges from 10% to 45% depending on the time of follow-up and prosthetic design; the success rate after revision averages 75% at midterm follow-up. The rate of infection reported in the literature varies between 2.9% and 12%. One stage revision may be considered after acute infection without signs of loosening, after which a success rate of 77.8% can be expected. Two stage revision is mainly indicated in multi-resistant microorganisms as well as septic loosening, with a success rate of 75% after 5 years. Deep infection represents the most serious complication in long-term follow-up, often leading to amputation due to soft tissue problems after tumour resection. The authors were able to confirm the minimal decrease in MSTS score despite the large number of operations (15 patients: nine females, six males; median MSTS score 84%; mean 81%).

Entities:  

Mesh:

Year:  2006        PMID: 16369846     DOI: 10.1007/s00132-005-0913-7

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  40 in total

1.  Two-stage revision for infected endoprostheses used in tumor surgery.

Authors:  Robert J Grimer; Mohan Belthur; C Chandrasekar; Simon R Carter; Roger M Tillman
Journal:  Clin Orthop Relat Res       Date:  2002-02       Impact factor: 4.176

2.  One-stage reimplantation for infected total knee arthroplasty.

Authors:  S B Göksan; M A Freeman
Journal:  J Bone Joint Surg Br       Date:  1992-01

3.  Etiology and results of tumor endoprosthesis revision surgery in 64 patients.

Authors:  P Z Wirganowicz; J J Eckardt; F J Dorey; F R Eilber; J M Kabo
Journal:  Clin Orthop Relat Res       Date:  1999-01       Impact factor: 4.176

Review 4.  Massive prostheses for malignant bone tumours of the limbs.

Authors:  S R Cannon
Journal:  J Bone Joint Surg Br       Date:  1997-05

5.  One-stage revision surgery for infected megaprostheses.

Authors:  G Holzer; R Windhager; R Kotz
Journal:  J Bone Joint Surg Br       Date:  1997-01

6.  Revision of the Kotz type of tumour endoprosthesis for the lower limb.

Authors:  F Mittermayer; R Windhager; M Dominkus; P Krepler; E Schwameis; M Sluga; R Kotz; G Strasser
Journal:  J Bone Joint Surg Br       Date:  2002-04

7.  One-stage revision of infected total hip replacements with discharging sinuses.

Authors:  V V Raut; P D Siney; B M Wroblewski
Journal:  J Bone Joint Surg Br       Date:  1994-09

8.  Knee function after operation for malignancy of the distal femur. Quadriceps muscle mass and knee extension strength in 21 patients with hinged endoprostheses.

Authors:  T Tsuboyama; R Windhager; W Dock; T Bochdansky; T Yamamuro; R Kotz
Journal:  Acta Orthop Scand       Date:  1993-12

9.  Prosthetic survival and clinical results with use of large-segment replacements in the treatment of high-grade bone sarcomas.

Authors:  M M Malawer; L B Chou
Journal:  J Bone Joint Surg Am       Date:  1995-08       Impact factor: 5.284

10.  Prosthetic and extremity survivorship after limb salvage for sarcoma. How long do the reconstructions last?

Authors:  S M Horowitz; D B Glasser; J M Lane; J H Healey
Journal:  Clin Orthop Relat Res       Date:  1993-08       Impact factor: 4.176

View more
  2 in total

1.  [Alloarthroplasty versus above-knee amputation].

Authors:  K Daniilidis; E Jakubowitz; C Stukenborg-Colsman; T Calließ; H Windhagen; D Yao
Journal:  Orthopade       Date:  2015-06       Impact factor: 1.087

2.  Direct exchange endoprosthetic reconstruction with tumour prosthesis for periprosthetic knee infection associated with segmental bone defects.

Authors:  Manjunath Ramappa; Ian McMurtry; Andrew Port
Journal:  Strategies Trauma Limb Reconstr       Date:  2010-01-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.